---
title: "AGEN.US (AGEN.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AGEN.US/news.md"
symbol: "AGEN.US"
name: "AGEN.US"
parent: "https://longbridge.com/en/quote/AGEN.US.md"
datetime: "2026-05-20T19:10:36.045Z"
locales:
  - [en](https://longbridge.com/en/quote/AGEN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AGEN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AGEN.US/news.md)
---

# AGEN.US (AGEN.US) — Related News

### [Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer | AGEN Stock News](https://longbridge.com/en/news/286608753.md)
*2026-05-15T12:11:00.000Z*
> Agenus Inc. announced the publication of Phase 1b data on botensilimab and balstilimab for treatment-refractory hepatoce

### [](https://longbridge.com/en/news/285977960.md)
*2026-05-11T16:41:22.000Z*
> Agenus shares are trading lower. The company reported its Q1 financial results.

### [Agenus | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 33.7 M](https://longbridge.com/en/news/285946187.md)
*2026-05-11T12:53:55.000Z*
### [Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development | AGEN Stock News](https://longbridge.com/en/news/285944609.md)
*2026-05-11T04:45:36.000Z*
> Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 De

### [Agenus Q1 2026 Earnings Preview](https://longbridge.com/en/news/285749281.md)
*2026-05-08T15:32:20.000Z*
> Agenus Q1 2026 Earnings Preview

### [Disrupting Scientific Friction: How Ome Ogbru Uses AI to Free Real Science](https://longbridge.com/en/news/285603607.md)
*2026-05-07T19:13:37.000Z*
> In the field of life sciences, innovation is crucial, but many companies continue to rely on inefficient workflows and m

### [Agenus (AGEN) Expected to Announce Earnings on Monday](https://longbridge.com/en/news/285090654.md)
*2026-05-04T15:04:36.000Z*
> Agenus (NASDAQ: AGEN) is set to announce its Q1 2026 earnings on May 11, with expectations of $1.95 per share and $129.5

### [Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer](https://longbridge.com/en/news/284913615.md)
*2026-05-01T15:10:41.000Z*
> Agendia, Inc. will present new FLEX Study data at ASBrS 2026, showing that MammaPrint and BluePrint consistently perform